Sökning: id:"swepub:oai:DiVA.org:uu-438963" >
In Vivo Evaluation ...
In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1
-
- Rubins, Daniel J. (författare)
- Merck & Co Inc, Translat Biomarkers Dept, West Point, PA 19486 USA.
-
- Meng, Xiangjun (författare)
- Merck & Co Inc, Translat Biomarkers Dept, West Point, PA 19486 USA.
-
- McQuade, Paul (författare)
- Merck & Co Inc, Translat Biomarkers Dept, West Point, PA 19486 USA.
-
visa fler...
-
- Klimas, Michael (författare)
- Merck & Co Inc, Translat Biomarkers Dept, West Point, PA 19486 USA.
-
- Getty, Krista (författare)
- Merck & Co Inc, Screening & Prot Sci Dept, West Point, PA USA.
-
- Lin, Shu-An (författare)
- Merck & Co Inc, Translat Biomarkers Dept, West Point, PA 19486 USA.
-
- Connolly, Brett M. (författare)
- Merck & Co Inc, Translat Biomarkers Dept, West Point, PA 19486 USA.
-
- O'Malley, Stacey S. (författare)
- Merck & Co Inc, Translat Biomarkers Dept, West Point, PA 19486 USA.
-
- Haley, Hyking (författare)
- Merck & Co Inc, Translat Biomarkers Dept, West Point, PA 19486 USA.
-
- Purcell, Mona (författare)
- Merck & Co Inc, Translat Biomarkers Dept, West Point, PA 19486 USA.
-
- Gantert, Liza (författare)
- Merck & Co Inc, Translat Biomarkers Dept, West Point, PA 19486 USA.
-
- Holahan, Marie (författare)
- Merck & Co Inc, Translat Biomarkers Dept, West Point, PA 19486 USA.
-
- Lindgren, Joel (författare)
- Affibody AB, Solna, Sweden.
-
- Eklund, Pär (författare)
- Affibody AB, Solna, Sweden.
-
- Ekblad, Caroline (författare)
- Affibody AB, Solna, Sweden.
-
- Frejd, Fredrik Y. (författare)
- Uppsala universitet,Medicinsk strålningsvetenskap,Affibody AB, Solna, Sweden.
-
- Hostetler, Eric D. (författare)
- Merck & Co Inc, Translat Biomarkers Dept, West Point, PA 19486 USA.
-
- Gonzalez Trotter, Dinko E. (författare)
- Merck & Co Inc, Translat Biomarkers Dept, West Point, PA 19486 USA.
-
- Evelhoch, Jeffrey L. (författare)
- Merck & Co Inc, Translat Biomarkers Dept, West Point, PA 19486 USA.
-
visa färre...
-
Merck & Co Inc, Translat Biomarkers Dept, West Point, PA 19486 USA Merck & Co Inc, Screening & Prot Sci Dept, West Point, PA USA. (creator_code:org_t)
- 2020-10-23
- 2021
- Engelska.
-
Ingår i: Molecular Imaging and Biology. - : Springer. - 1536-1632 .- 1860-2002. ; 23, s. 241-249
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Purpose: In vivo imaging of programmed death ligand 1 (PD-L1) during immunotherapy could potentially monitor changing PD-L1 expression and PD-L1 expression heterogeneity within and across tumors. Some protein constructs can be used for same-day positron emission tomography (PET) imaging. Previously, we evaluated the PD-L1-targeting Affibody molecule [F-18]AlF-NOTA-Z(PD-L1_1) as a PET tracer in a mouse tumor model of human PD-L1 expression. In this study, we evaluated the affinity-matured Affibody molecule Z(PD-L1_4), to determine if improved affinity for PD-L1 resulted in increased in vivo targeting of PD-L1.Procedures: Z(PD-L1_4) was conjugated with NOTA and radiolabeled with either [F-18]AlF or Ga-68. [F-18]AlF-NOTA-Z(PD-L1_4) and [Ga-68]NOTA-Z(PD-L1_4) were evaluated in immunocompromised mice with LOX (PD-L1+) and SUDHL6 (PD-L1-) tumors with PET and ex vivo biodistribution measurements. In addition, whole-body PET studies were performed in rhesus monkeys to predict human biodistribution in a model with tracer binding to endogenous PD-L1, and to calculate absorbed radiation doses.Results: Ex vivo biodistribution measurements showed that both tracers had > 25 fold higher accumulation in LOX tumors than SUDHL6 ([F-18]AlF-NOTA-Z(PD-L1_4): LOX: 8.7 +/- 0.7 %ID/g (N = 4) SUDHL6: 0.2 +/- 0.01 %ID/g (N = 6), [Ga-68]NOTA-Z(PD-L1_4): LOX: 15.8 +/- 1.0 %ID/g (N = 6) SUDHL6: 0.6 +/- 0.1 %ID/g (N = 6)), considerably higher than Z(PD-L1_1). In rhesus monkeys, both PET tracers showed fast clearance through kidneys and low background signal in the liver ([F-18]AlF-NOTA-Z(PD-L1_4): 1.26 +/- 0.13 SUV, [Ga-68]NOTA-Z(PD-L1_4): 1.11 +/- 0.06 SUV). PD-L1-expressing lymph nodes were visible in PET images, indicating in vivo PD-L1 targeting. Dosimetry estimates suggest that both PET tracers can be used for repeated clinical studies, although high kidney accumulation may limit allowable radioactive doses.Conclusions: [F-18]AlF-NOTA-Z(PD-L1_4) and [Ga-68]NOTA-Z(PD-L1_4) are promising candidates for same-day clinical PD-L1 PET imaging, warranting clinical evaluation. The ability to use either [F-18] or [Ga-68] may expand access to clinical sites.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Radiologi och bildbehandling (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Radiology, Nuclear Medicine and Medical Imaging (hsv//eng)
Nyckelord
- PD-L1
- PET
- Oncology PET imaging
- Molecular imaging
- Affibody molecules
- Translational research
- Oncology biomarker
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Rubins, Daniel J ...
-
Meng, Xiangjun
-
McQuade, Paul
-
Klimas, Michael
-
Getty, Krista
-
Lin, Shu-An
-
visa fler...
-
Connolly, Brett ...
-
O'Malley, Stacey ...
-
Haley, Hyking
-
Purcell, Mona
-
Gantert, Liza
-
Holahan, Marie
-
Lindgren, Joel
-
Eklund, Pär
-
Ekblad, Caroline
-
Frejd, Fredrik Y ...
-
Hostetler, Eric ...
-
Gonzalez Trotter ...
-
Evelhoch, Jeffre ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Radiologi och bi ...
- Artiklar i publikationen
-
Molecular Imagin ...
- Av lärosätet
-
Uppsala universitet